Summary:
- This article discusses the development and testing of a new COVID-19 vaccine candidate called BG18. The vaccine was found to be highly effective in protecting against the original SARS-CoV-2 strain as well as several variants of concern.
- The vaccine works by targeting the receptor-binding domain of the SARS-CoV-2 spike protein, which is a key part of the virus that allows it to infect human cells. The vaccine triggers a strong immune response, including the production of neutralizing antibodies.
- Clinical trials showed the BG18 vaccine to be safe and well-tolerated, with no serious adverse events reported. The vaccine demonstrated high levels of efficacy against both symptomatic and severe COVID-19 disease.